HW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of	: Mario G. Cardozo, et al.) Art Unit:	Not Yet Assigned
U.S. Appln. No.	: 10/766,079) Examiner:	Not Yet Assigned
Confirmation No.	. 2420		

Confirmation No.: 2420 U.S. Filing Date: 01/27/2004

Title of Invention: Pyrimidine derivatives useful as inhibitors of PKC-theta

Attny. Docket No.: 9/271

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

August 10, 2004

Sir:

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.
1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.
1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:
A statement as specified in 37 C.F.R. §1.97(e) [see below]; or
The fee set forth in 37 C.F.R. §1.17(p).

		\$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
	ent as s	This Statement is being filed after the period specified in 37 C.F.R. on or before payment of the issue fee. This Statement is accompanied by a specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e).
	counte	Each item of information contained in the instant information disclosure tent was first cited in any communication from a foreign patent office in a expart foreign application not more than three (3) months prior to the filing of stant information disclosure statement; or
	foreign makin inform §1.56(No item of information contained in the instant information disclosure tent was cited in a communication from a foreign patent office in a counterpart in application, and, to the knowledge of the person signing this certification after greasonable inquiry, no item of information contained in the instant nation disclosure statement was known to any individual designated in 37 C.F.R. (c) more than three (3) months prior to the filing of the instant information sure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte in sect	rpart ap	(d). Each item of information contained in the accompanying information tement was cited in a communication from a foreign patent office in a oplication, which communication was not received by any individual designated 6(c) more than thirty (30) days prior to the filing of the accompanying isclosure statement

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Philip I. Datlow

Attorney for Applicant(s)

Reg. No. 41,482

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4542 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on August 10, 2004.

Philip I. Datlow, Reg. No. 41,482

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/766,079

Filing Date 01/27/2004

First Named Inventor Mario G. Cardozo

Art Unit Not Yet Assigned

Examiner Name Not Yet Assigned

Attorney Docket Number 9/271

	U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
-		Number-Kind Code ² (* known) US- 2003/0171359 A1	09-11-2003	Georg Dahmann, et al.				
	1	^{US-} 6,432,963 B1	08-13-2002	Hiroyuki Hisamichi, et al.				
· -		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
-		US-						
		US-			A - 100 - 10			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Т6	
		Country Code ³ Number ⁴ Kind Code ⁵ (# known) WO 00/75113 A1	12-14-2000	YAMANOUCHI PHARMACEUTICAL CO., LTD.	or Relevant Figures Appear		
	 	WO 02/096887 A1	12-05-2002	ASTRAZENECA AB			
		WO 02/030867 A1		ALTANA PHARMA AG			
***************************************	ł	WO 02/096888 A1	10 05 0000	SCHERING AKTIENGESELLSCHAFT			
	ļ	WO 97/19065	05-29-1997	CELLTECH THERAPEUTICS LIMITED	***************************************		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Panerwork Reduction Act of 1995, no persons are required to re Substitute for form 1449A/PTO		Complete if Known			
			Application Number	10/766,079	
	INFORMATION DISC	CLOSURE	Filing Date	01/27/2004	_
	STATEMENT BY AF	PLICANT	First Named Inventor	Mario G. Cardozo	
		. 2.0,	Art Unit	Not Yet Assigned	·
	(Use as many sheets as ne	cessary)	Examiner Name	Not Yet Assigned	
Sh	eet 2	of 2	Attorney Docket Number	9/271	

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
,		US-			
		US-			
		US-			
***		US-			
		US-			
		US-			***************************************
110000 - 10000		US-	······································		A. I. M
		US-			
		US-			
***** ***** ****		US-	· · · · · · · · · · · · · · · · · · ·		and the state of t
THE P STREET		US∙			
		US-			
Course of Colony Con-		US-		**************************************	**************************************
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ 'Number ⁴ 'Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
		WO 01/00213 A1	01-04-2001	MERCK & CO., INC.	***************************************	
	ļ		•••••			
	ļ		•••••		XX	
	ļ				***************************************	Ш

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.